Summary:
During HIV-1 infection, vitamin A deficiency is common (1) and an independent risk factor for adult mortality (2, 3) . Modest increases in vitamin A intake by HIV-infected people are associated with improved vitamin A status (4) and slower progression to AIDS (5) . Among HIV-infected pregnant women, low serum retinol concentration is a risk factor for infant mortality (6,7), mother-to-child HIV transmission (8) , and a greater likelihood of detecting HIV DNA in colostrum (9) . These infection with HIV increases virus production (11) (12) (13) . In one study, retinol (the form in circulation) or retinyl acetate (the form in food and supplements) produced similar effects, leading these authors to suggest that "use of retinoids in HIV-infected patients should be with caution" (13) . Conversely, when retinoic acid treatment was begun concurrently with transfection, the upregulatory effect of retinoic acid treatment was greatly reduced (13) and when retinoid supplementation was begun several days after infection, it either had no effect (J. Turpin, plasma concentrations rise from ~50 nM to ~15,000 nM during the 6 hours after dosing, and then rapidly fall near baseline within 6 to 24 hours (16) . The effects of this brief but unique metabolic state on HIV expression may be different than that of physiologic doses of vitamin A.
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Design and Subjects
The study was a randomized, double-masked, placebo- (18) and of an AIDS-associated illness (e.g., swollen glands, anorexia, diarrhea, weight loss, fever or night sweats, and fatigue) during the previous month were documented. Because this was a safety study, the trial was conducted among two cohorts of women to limit the number of women exposed should the intervention prove to be harmful. The first 18 women participated from January 20 to March 20, 1996.
Following a review of these data by an outside Data Safety and
Monitoring Committee (DSMC), a second cohort of 22 women was studied from May 5 to July 5, 1996. One of these women failed to return for all follow-up visits so data are reported for 39 women.
The investigators remained masked to treatment allocation until after the DSMC conducted a second review of the data generated by all 39 women. The purpose of this second review was to detect any trends in the data that might reach statistical significance if additional women were studied. The DSMC concluded that the sample size was sufficient. 
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Statistical Analysis
Proportions were compared with [chi] 2 or Fisher's exact tests and means were compared using t-tests. Medians and geometric means were calculated as measures of central tendency for skewed data (i.e., viral load, lymphocyte subsets) and groups were compared using nonparametric tests. All statistical tests were two-tailed, except the side effect data in which one-tailed tests were used. Level of significance used was p < .05. 
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Comparability of Treatment Groups
At baseline, no significant differences were found between the vitamin A-treated and placebo-treated groups in age, the proportion of women who had had at least one documented AIDSdefining illness, or the proportion of women who reported at least one episode of AIDS-associated illness in the previous month (Table 1 ). In the vitamin A group, 10 (45.4%) and in the placebo group, 11 (61.1%) women were not receiving antiretroviral drugs (p = .50), and the remaining women in both groups were taking zidovudine (ZDV), didanosine (ddI), dideoxycytidine (ddC), stavudine (d4T), lamivudine (3TC), or a combination of two of these drugs. One woman in the vitamin A group was concurrently enrolled in ACTG-276 and taking her prescribed drug. None of the women reported taking any of the new protease inhibitors. Table 1 Back to Top Tolerance Administration of a single 9900-µmol dose of vitamin A was well tolerated: rates of headache, nausea, vomiting, diarrhea, and fever reported by vitamin A recipients were no different compared with those reported by placebo recipients at either 24 hours or 1 week after dosing (Table 2) . Table 2 Back to Top
Impact of Supplementation on Vitamin A Status
Serum retinol concentration was normal (>1.05 µmol/L) in the majority of women at baseline, though concentrations were below this cutoff for four women (3 vitamin A, 1 placebo). No change was found in the mean or median serum retinol concentrations in either treatment group 4 weeks after supplementation (Table 3) . 
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Plasma HIV-1 RNA (Viral Load) Response to Vitamin A Supplementation Serial measures of log10 plasma HIV RNA (copies/ml) are plotted for each woman in the vitamin A group (Fig. 3, top) and placebo group (Fig. 3, bottom) . Dashed lines in Figure 3 represent ± 0.5 log10 of the woman's baseline viral load, the conventional cutoff used for disease progression or improvement; in this paper, we define a change in viral load of this magnitude or greater as being clinically "significant." We carefully compared all reported morbidity and changes in type or dosage of anti-retroviral drug therapy and were unable to explain fluctuations in viral load based on these factors for any woman except ID 43 who began 3TC at week 2 and thereafter experienced a significant decline in viral load. Geometric mean viral load concentration was very similar for the two groups at all time points (p >= .44; Fig. 4 ). We had 80% power to detect a difference of 0.72 log in geometric means. Similarly, no differences were observable between groups in median viral load levels at any time point (p >= .24; data not shown). 
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